Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

Introduction The treatment of diabetes has a significant impact on the pathogenesis of non-alcoholic fatty liver disease (NAFLD). We compared the effectiveness of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, and pioglitazone for the treatment of NAFLD patients with type 2 dia...

Full description

Saved in:
Bibliographic Details
Main Authors: Atsushi Nakajima, Takeharu Yamanaka, Yasushi Honda, Kento Imajo, Masataka Taguri, Masato Yoneda, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, Asako Nogami, Hiroyuki Kirikoshi, Tomoyuki Iwasaki, Takeo Kurihashi, Satoru Saito
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/9/1/e001990.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items